Stock listing

NASDAQ:SNOA Sonoma Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Sonoma Pharmaceuticals, Inc.

Follow Sonoma Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SNOA

$0.722 USD -0.106 (-12.8%)

Close on Nov 20, 2026

Past year -77.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.722 – $0.840 USDNov 20, 2026
Volume
103,744 sharesNov 20, 2026
Market cap
$3.65M USDAt the close on Nov 20, 2026 · price × 5.06M shares outstanding
52-week range
$0.722 – $3.950 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$72,898 USDMedian day 47,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sonoma Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SNOA · Home$0.722 USD-0.106 (-12.8%)103,744$0.800$0.840$0.722$0.828Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SNOA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.722-0.106-12.8%$0.800$0.840$0.722103,744
$0.828-0.006-0.8%$0.851$0.853$0.79768,845
$0.834-0.046-5.2%$0.880$0.880$0.83097,324
$0.880-0.210-19.2%$1.070$1.100$0.800425,193
$1.090-0.080-6.8%$1.200$1.200$1.08094,745
$1.170-0.070-5.6%$1.260$1.270$1.150157,742
$1.240+0.100+8.8%$1.260$1.299$1.180324,217
$1.140+0.010+0.9%$1.091$1.170$1.09191,339
$1.130+0.020+1.8%$1.170$1.190$1.10226,682
$1.110+0.040+3.7%$1.100$1.148$1.08043,572
$1.070-0.040-3.6%$1.130$1.145$1.07055,268
$1.110-0.030-2.6%$1.130$1.160$1.1059,966
$1.140+0.040+3.6%$1.090$1.160$1.08036,662
$1.1000.0000.0%$1.080$1.150$1.05042,242
$1.100-0.100-8.3%$1.160$1.170$1.07085,814
$1.200+0.060+5.3%$1.184$1.200$1.16220,237
$1.140-0.010-0.9%$1.140$1.180$1.11950,626
$1.150+0.030+2.7%$1.100$1.160$1.10033,670
$1.120+0.010+0.9%$1.120$1.200$1.10062,801
$1.110-0.040-3.5%$1.130$1.130$1.11045,900
$1.150+0.010+0.9%$1.130$1.170$1.12016,900
$1.140-0.010-0.9%$1.170$1.190$1.12011,800
$1.150+0.030+2.7%$1.160$1.170$1.13010,600
$1.1200.0000.0%$1.110$1.150$1.10042,600
$1.120-0.030-2.6%$1.230$1.230$1.12056,900
$1.150-0.010-0.9%$1.150$1.210$1.12031,300
$1.160-0.020-1.7%$1.160$1.180$1.13049,100
$1.180-0.050-4.1%$1.250$1.250$1.17047,700
$1.2300.0000.0%$1.240$1.290$1.22014,800
$1.230+0.070+6.0%$1.170$1.260$1.16049,300
$1.160-0.060-4.9%$1.200$1.200$1.14089,000
$1.220-0.010-0.8%$1.230$1.230$1.20031,600
$1.230+0.010+0.8%$1.270$1.270$1.21044,700
$1.220-0.020-1.6%$1.240$1.250$1.22018,600
$1.240-0.010-0.8%$1.280$1.290$1.22027,400
$1.250-0.030-2.3%$1.310$1.310$1.25035,300
$1.280+0.030+2.4%$1.240$1.300$1.200110,700
$1.250-0.010-0.8%$1.270$1.280$1.2407,600
$1.260-0.010-0.8%$1.290$1.290$1.24030,400
$1.270+0.020+1.6%$1.240$1.290$1.24024,300
$1.2500.0000.0%$1.240$1.290$1.20077,700
$1.250-0.050-3.8%$1.310$1.310$1.25041,500
$1.300+0.050+4.0%$1.270$1.300$1.26014,400
$1.250-0.030-2.3%$1.280$1.280$1.25027,600
$1.280+0.020+1.6%$1.260$1.340$1.240147,400
$1.260+0.030+2.4%$1.240$1.270$1.2407,700
$1.230-0.050-3.9%$1.280$1.280$1.230106,100
$1.280-0.010-0.8%$1.300$1.300$1.27071,100
$1.290-0.020-1.5%$1.300$1.300$1.28022,100
$1.3100.0000.0%$1.340$1.340$1.29023,000
$1.310+0.010+0.8%$1.300$1.310$1.29032,200
$1.300-0.030-2.3%$1.330$1.340$1.30030,700
$1.3300.0000.0%$1.350$1.360$1.31043,500
$1.330+0.010+0.8%$1.300$1.330$1.28092,800
$1.320+0.030+2.3%$1.300$1.320$1.29047,300
$1.2900.0000.0%$1.300$1.310$1.29023,400
$1.2900.0000.0%$1.280$1.310$1.26072,500
$1.290-0.020-1.5%$1.280$1.310$1.27095,800
$1.310-0.020-1.5%$1.330$1.370$1.28092,400
$1.330-0.050-3.6%$1.400$1.400$1.33060,300
$1.380+0.030+2.2%$1.340$1.410$1.34062,400
$1.350+0.010+0.7%$1.360$1.360$1.32047,341
$1.3400.0000.0%$1.330$1.350$1.32063,406
$1.3400.0000.0%$1.330$1.360$1.32066,600
$1.340-0.020-1.5%$1.370$1.380$1.31076,000

Splits

4 splits since 2013 · NASDAQ:SNOA · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-9Consolidation
1-for-5Consolidation
1-for-7Consolidation
Ticker
NASDAQ:SNOA
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Sonoma Pharmaceuticals, Inc. news

Sonoma Pharmaceuticals, Inc. on 6ix

News releases
10 in the last 12 months · 102 in all · newest Nov 10, 2026 · oldest 2019
Decks
21 decks · latest January 2026

Where Sonoma Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SNOA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SNOABOATSUnited StatesUSD
Lang & Schwarz:A40M9JLang & SchwarzGermanyEUR
Munich:O8ZMunichGermanyEUR
Frankfurt:O8ZFrankfurtGermanyEUR
Stuttgart:O8ZStuttgartGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$352,530 USD
P/E
Loss
EV/sales
−0.0×
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
39.2%
Operating margin
−3.3%
Net margin
−7.6%
Debt to equity
0.1×
Beta vs S&P 500
1.53

Forecasts

Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
12.00 USD · Analysts' mean
EPS, year to Mar 2026
-1.61 · 1 analyst

Events

QuarterResultsShare move
Q2 2027Nov 10, 2026+9.7%
Q1 2027Aug 6, 2026+27.4%
Q4 2026Jun 16, 2026+3.6%
Q3 2026Feb 10, 2026 · After close+1.4%
Q2 2026Nov 4, 2025 · Before open−0.5%
Q1 2026Aug 7, 2025 · After close−1.6%
Q4 2025Jun 17, 2025−7.5%
Q3 2025Feb 5, 2025 · After close−0.4%
Q2 2025Nov 7, 2024 · Before open+2.1%
Q1 2025Aug 8, 2024 · After close−19.4%
All 20 quarters
QuarterResultsShare move
Q4 2024Jun 17, 2024 · After close+11.8%
Q3 2024Feb 8, 2024 · After close0.0%
Q2 2024Nov 13, 2023 · After close0.0%
Q1 2024Aug 10, 2023 · After close−3.0%
Q4 2023Jun 21, 2023 · After close+3.5%
Q3 2023Feb 14, 2023 · After close+1.3%
Q2 2023Nov 14, 2022 · After close+7.2%
Q1 2023Aug 11, 2022 · After close−0.9%
Q3 2022Feb 11, 2022 · After close−6.9%
Quarter to Sep 30, 2021Nov 15, 2021 · Before open−3.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck30 slidesJanuary 2026
Investor Presentation (September 2025)Investor deck30 slidesSep 29, 2025
Investor Presentation (April 2025)Investor deck31 slidesApr 28, 2025
Investor Presentation (April 2025)Investor deck31 slidesApr 7, 2025
Investor Presentation (October 2024)Investor deck33 slidesOct 22, 2024
Investor Presentation (April 2024)Investor deck32 slidesApr 9, 2024
Investor Presentation (April 2024)Investor deck32 slidesApr 2, 2024
Investor Presentation (January 2024)Investor deck28 slidesJan 10, 2024
Investor Presentation (May 2023)Investor deck23 slidesMay 10, 2023
Investor Presentation (January 2023)Investor deck31 slidesJan 6, 2023
All 21 decks
DeckKindSlidesDate
Investor Presentation (January 2022)Investor deck29 slidesJan 6, 2022
Investor Presentation (March 2021)Investor deck27 slidesMar 4, 2021
Investor Presentation (January 2021)Investor deck27 slidesJan 11, 2021
Q2 FY2019 Earnings PresentationEarnings11 slidesNov 8, 2018
Q1 FY2019 Earnings PresentationEarnings8 slidesAug 8, 2018
Q4 FY2018 Earnings PresentationEarnings8 slidesJun 13, 2018
Q3 FY2018 Earnings PresentationEarnings9 slidesFeb 7, 2018
Q2 FY2018 Earnings PresentationEarnings11 slidesNov 9, 2017
Oculus Innovative Sciences — Dawson James Investor Conference 2015Conference22 slidesOct 15, 2015
Oculus Innovative Sciences — Investor Presentation (May 2013)Investor deck27 slidesMay 30, 2013
Oculus Innovative Sciences — Corporate Update (June 2012)Corporate update5 slidesJun 7, 2012

Open Decks

Financings

RaiseDate
Public offering of shares of common stock and warrants
Announced: about US$4M · US$1.35 a share · Warrants at US$1.35 · Dawson James Securities
Dealers: Dawson James Securities (lead)
Use of proceeds: General corporate purposes, including working capital
Apr 24, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Oculus Innovative Sciences, Inc. Priced at US$8.00 a share on Jan 26, 2007.

Price
US$8.00 a share
Shares offered
3,025,000 shares of common stock
Offering size
US$24.2 million
Underwriters
ROTH CAPITAL PARTNERS, MAXIM GROUP LLC, BROOKSTREET SECURITIES CORPORATION · In the order on the cover
Shares delivered
On or about Jan 30, 2007

Steps

StepWhen
Filed publiclyJul 3, 2006
Amended 7 timesNewest Jan 8, 2007
Shares registered with an exchangeDec 15, 2006
Declared effective by the SECJan 24, 2007
Final prospectus, with the priceJan 26, 2007

Open IPO · From the cover of the final prospectus (424B4) filed Jan 26, 2007

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue19.5M14.3M12.7M13.3M12.6M18.6M17.9M19.0M16.7M12.8M
Cost of revenue12.1M8.82M7.99M8.79M8.63M12.1M9.81M10.1M9.35M7.16M
Gross profit7.42M5.46M4.75M4.48M3.99M6.56M8.12M8.88M7.31M5.67M
Research and development2.27M1.81M1.87M207.0K125.0K555.0K1.34M1.52M1.57M1.58M
Selling, general and administrative7.61M7.36M7.58M8.84M9.76M9.45M14.2M18.6M19.9M17.1M
Operating income-2.46M-3.71M-4.70M-4.57M-5.89M-3.45M-7.39M-11.3M-14.2M-13.0M
Depreciation and amortization139.0K138.0K176.0K125.0K186.0K227.0K312.0K453.0K490.0K248.0K
EBITDA-2.32M-3.57M-4.53M-4.45M-5.70M-3.22M-7.08M-10.8M-13.7M-12.7M
Interest expense16.0K10.0K12.0K16.0K33.0K40.0K3.00K
Income before tax-3.42M-2.91M-5.03M-5.18M-5.42M-3.90M-3.54M-11.3M-14.3M-12.9M
Income tax-244.0K550.0K-196.0K-33.0K-332.0K713.0K29.0K458.0K50.0K-4.27M
Net income-3.17M-3.46M-4.83M-5.15M-5.09M-3.95M-3.31M-11.8M-14.3M9.27M
Earnings per share, basic-1.89-2.79-10.63-1.52-1.92-1.97-2.24-12.77-28.492.20
Earnings per share, diluted-1.89-2.79-10.63-1.52-1.92-1.97-2.24-12.77-28.492.20

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents2.40M5.37M3.13M3.82M7.40M4.22M3.69M3.69M10.1M17.5M
Short-term investments00
Receivables2.53M2.23M2.90M2.57M2.41M2.81M3.97M3.48M1.54M2.11M
Inventory3.65M2.92M2.72M2.86M2.66M2.53M2.18M3.41M2.87M2.22M
Current assets12.1M12.6M12.5M13.8M16.4M13.0M12.3M12.5M16.3M22.6M
Property, plant and equipment310.0K225.0K365.0K488.0K320.0K360.0K365.0K727.0K1.14M1.24M
Goodwill00
Total assets14.0M13.7M14.7M16.2M18.8M15.0M14.6M14.4M19.2M25.5M
Accounts payable1.92M953.0K607.0K841.0K1.64M1.77M2.07M1.25M1.27M1.25M
Current liabilities4.83M4.10M3.72M3.72M5.82M4.08M4.73M3.59M3.26M3.29M
Long-term debt01.31M012.0K32.0K45.0K
Total debt842.0K305.0K608.0K849.0K01.91M481.0K334.0K262.0K172.0K
Total liabilities10.9M9.28M8.60M8.25M10.1M9.62M8.94M3.96M3.88M4.03M
Shareholders' equity3.10M4.41M6.14M7.98M8.70M5.36M5.62M7.77M15.3M21.4M
Shares outstanding1.80M1.63M780.4K4.93M3.10M2.09M1.78M1.32M685.7K4.29M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-3.93M-88.0K-2.40M-6.15M-4.25M-3.38M-4.59M-11.7M-12.4M-8.17M
Capital spending-192.0K-80.0K-2.00K-269.0K-137.0K-179.0K-206.0K-100.0K-187.0K-394.0K
Free cash flow-4.13M-168.0K-2.40M-6.42M-4.38M-3.56M-4.80M-11.8M-12.6M-8.56M
Cash from investing-192.0K-80.0K-2.00K-258.0K-99.0K388.0K3.64M-131.0K-201.0K18.2M
Cash from financing477.0K3.03M1.68M2.49M7.40M3.31M1.03M5.49M5.24M-32.0K
Dividends paid00
Share buybacks0-1.00K03.60M1.38M5.97M5.52M98.0K
Change in cash-2.98M2.25M-692.0K-3.58M3.18M529.0K2.00K-6.38M-7.39M9.99M

Open Financials

Filings

FilingDateTypeFiled with
S-3 · Registration statementNov 13, 2026Offer documentSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedOct 6, 2026Other filingsSEC
8-K · Current reportOct 6, 2026Material contractSEC
8-K · Current reportSep 16, 2026Meeting outcomeSEC
8-K · Current reportAug 19, 2026Meeting outcomeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
DEF 14A · Proxy statementJul 28, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialJul 22, 2026Meeting noticeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJul 9, 2026Offer documentSEC
DEFA14A · Additional proxy materialJun 24, 2026Meeting noticeSEC
8-K · Current reportJun 18, 2026Current reportSEC
424B5 · ProspectusJun 18, 2026Offer documentSEC
10-K · Annual reportJun 16, 2026Annual reportSEC
DEF 14A · Proxy statementMay 5, 2026Meeting noticeSEC
8-K · Current reportApr 30, 2026Material contractSEC
424B4 · ProspectusApr 27, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementApr 24, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 24, 2026Other filingsSEC
CORRESP · Letter to the SECApr 22, 2026Other filingsSEC
S-1/A · Registration statement, amendedApr 22, 2026Offer documentSEC
CORRESP · Letter to the SECApr 22, 2026Other filingsSEC
S-1 · Registration statementApr 17, 2026Offer documentSEC
UPLOAD · Letter from the SECApr 10, 2026Other filingsSEC
DRS · Draft registration statementApr 9, 2026Offer documentSEC
8-K · Current reportApr 9, 2026Material contractSEC
10-Q · Quarterly reportFeb 10, 2026Quarterly reportSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
8-K · Current reportJan 28, 2026Management or board changeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
8-K · Current reportJan 2, 2026Management or board changeSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportOct 23, 2025Management or board changeSEC
8-K · Current reportOct 9, 2025Management or board changeSEC
8-K · Current reportSep 29, 2025Current reportSEC
8-K · Current reportSep 26, 2025Material contractSEC
424B5 · ProspectusSep 26, 2025Offer documentSEC
8-K · Current reportAug 29, 2025Meeting outcomeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
DEF 14A · Proxy statementJul 11, 2025Meeting noticeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJun 17, 2025Offer documentSEC
10-K · Annual reportJun 17, 2025Annual reportSEC
8-K · Current reportApr 28, 2025Current reportSEC
8-K · Current reportApr 7, 2025Current reportSEC
8-K · Current reportMar 25, 2025Material contractSEC
10-Q · Quarterly reportFeb 5, 2025Quarterly reportSEC
8-K · Current reportJan 30, 2025Material contractSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
8-K · Current reportJan 3, 2025Management or board changeSEC
144 · Notice of proposed saleJan 3, 2025Other filingsSEC
144/A · Notice of proposed sale, amendedJan 3, 2025Other filingsSEC
144/A · Notice of proposed sale, amendedJan 3, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleDec 26, 2024Other filingsSEC
S-8 · Registration statement for employee plansDec 20, 2024Offer documentSEC
8-K · Current reportNov 21, 2024Current reportSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportOct 22, 2024Material contractSEC
8-K · Current reportSep 20, 2024Current reportSEC
424B5 · ProspectusSep 20, 2024Offer documentSEC
8-K · Current reportAug 28, 2024Meeting outcomeSEC
8-K · Current reportAug 22, 2024Current reportSEC
424B5 · ProspectusAug 22, 2024Offer documentSEC
8-K · Current reportAug 21, 2024Material contractSEC
DEFA14A · Additional proxy materialAug 14, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialAug 14, 2024Meeting noticeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialJul 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementJul 1, 2024Meeting noticeSEC
8-K · Current reportJun 27, 2024Current reportSEC
424B5 · ProspectusJun 27, 2024Offer documentSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
PRE 14A · Preliminary proxy statementJun 21, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansJun 17, 2024Offer documentSEC
10-K · Annual reportJun 17, 2024Annual reportSEC
8-K · Current reportApr 9, 2024Current reportSEC
8-K · Current reportApr 2, 2024Current reportSEC
8-K · Current reportMar 22, 2024Current reportSEC
8-K · Current reportMar 8, 2024Material contractSEC
424B3 · ProspectusMar 8, 2024Offer documentSEC
10-Q · Quarterly reportFeb 8, 2024Quarterly reportSEC
8-K · Current reportJan 10, 2024Current reportSEC
8-K · Current reportJan 9, 2024Material contractSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
8-K · Current reportDec 29, 2023Management or board changeSEC
8-K · Current reportDec 15, 2023Material contractSEC
424B3 · ProspectusDec 15, 2023Offer documentSEC
424B5 · ProspectusNov 22, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 21, 2023Other filingsSEC
CORRESP · Letter to the SECNov 17, 2023Other filingsSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
UPLOAD · Letter from the SECNov 7, 2023Other filingsSEC
S-3 · Registration statementNov 3, 2023Offer documentSEC
424B4 · ProspectusOct 30, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 27, 2023Other filingsSEC
CORRESP · Letter to the SECOct 24, 2023Other filingsSEC
CORRESP · Letter to the SECOct 24, 2023Other filingsSEC
CORRESP · Letter to the SECOct 13, 2023Other filingsSEC
S-1/A · Registration statement, amendedOct 13, 2023Offer documentSEC
8-K/A · Current report, amendedOct 11, 2023Current reportSEC
8-K · Current reportOct 11, 2023Current reportSEC
8-K · Current reportSep 28, 2023Meeting outcomeSEC
UPLOAD · Letter from the SECSep 27, 2023Other filingsSEC
S-1 · Registration statementSep 19, 2023Offer documentSEC
DEFA14A · Additional proxy materialSep 14, 2023Meeting noticeSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
DEF 14A · Proxy statementJul 27, 2023Meeting noticeSEC
3 · Initial statement of ownershipJul 21, 2023Insider tradeSEC
8-K · Current reportJul 14, 2023Management or board changeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
10-K · Annual reportJun 21, 2023Annual reportSEC
8-K · Current reportMay 10, 2023Current reportSEC
3 · Initial statement of ownershipApr 13, 2023Insider tradeSEC
8-K · Current reportApr 13, 2023Management or board changeSEC
424B5 · ProspectusFeb 24, 2023Offer documentSEC
8-K · Current reportFeb 24, 2023Material contractSEC
10-Q · Quarterly reportFeb 14, 2023Quarterly reportSEC
8-K · Current reportJan 31, 2023Material contractSEC
8-K · Current reportJan 6, 2023Current reportSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
8-K · Current reportDec 30, 2022Management or board changeSEC
8-K · Current reportDec 23, 2022Material contractSEC
424B3 · ProspectusDec 23, 2022Offer documentSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
3 · Initial statement of ownershipOct 12, 2022Insider tradeSEC
8-K · Current reportOct 7, 2022Management or board changeSEC
8-K · Current reportSep 16, 2022Meeting outcomeSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
DEF 14A · Proxy statementJul 22, 2022Meeting noticeSEC
8-K · Current reportJul 22, 2022Management or board changeSEC
10-K · Annual reportJul 13, 2022Annual reportSEC
NT 10-K · Late filing noticeJun 29, 2022Explanation requestSEC
10-Q · Quarterly reportFeb 11, 2022Quarterly reportSEC
8-K · Current reportJan 20, 2022Material contractSEC
4 · Change in ownershipJan 14, 2022Insider tradeSEC
4 · Change in ownershipJan 14, 2022Insider tradeSEC
4 · Change in ownershipJan 14, 2022Insider tradeSEC
4 · Change in ownershipJan 14, 2022Insider tradeSEC
4 · Change in ownershipJan 14, 2022Insider tradeSEC
4 · Change in ownershipJan 14, 2022Insider tradeSEC
8-K · Current reportJan 14, 2022Management or board changeSEC
S-8 · Registration statement for employee plansJan 13, 2022Offer documentSEC
8-K · Current reportJan 6, 2022Current reportSEC
10-Q · Quarterly reportNov 15, 2021Quarterly reportSEC
8-K · Current reportNov 9, 2021Material contractSEC
8-K · Current reportSep 21, 2021Meeting outcomeSEC
8-K · Current reportSep 3, 2021Current reportSEC
424B3 · ProspectusSep 3, 2021Offer documentSEC
DEFA14A · Additional proxy materialAug 30, 2021Meeting noticeSEC
DEFA14A · Additional proxy materialAug 23, 2021Meeting noticeSEC
10-Q · Quarterly reportAug 16, 2021Quarterly reportSEC
DEFA14A · Additional proxy materialAug 16, 2021Meeting noticeSEC
8-K · Current reportAug 2, 2021Management or board changeSEC
8-K · Current reportJul 30, 2021Material contractSEC
424B3 · ProspectusJul 30, 2021Offer documentSEC
DEF 14A · Proxy statementJul 29, 2021Meeting noticeSEC
8-K · Current reportJul 20, 2021Current reportSEC
10-K · Annual reportJul 14, 2021Annual reportSEC
8-K · Current reportJul 9, 2021Current reportSEC
8-K · Current reportJul 6, 2021Management or board changeSEC
NT 10-K · Late filing noticeJun 29, 2021Explanation requestSEC
8-K · Current reportMar 31, 2021Material contractSEC
8-K · Current reportMar 4, 2021Current reportSEC
10-Q · Quarterly reportFeb 16, 2021Quarterly reportSEC
4 · Change in ownershipJan 13, 2021Insider tradeSEC

This page holds 200 of 979 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Sonoma Pharmaceuticals, Inc.’s releases · as of Nov 10, 2026

Common shares
5,061,593
Fully diluted
5,061,593

Fully diluted

LineSharesAs of
Common shares5,061,593Nov 10, 2026

Share count over time

CountShares
Nov 10, 20265,061,593
Sep 30, 20265,057,755
Sep 30, 20265,057,755

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Renaissance Technologies77,4001.5%US$99,072Sep 30, 2026
Citadel67,9651.3%US$86,995Sep 30, 2026
Vanguard57,6471.1%US$73,788Sep 30, 2026
Geode Capital55,5051.1%US$71,045Sep 30, 2026
Jane Street21,0000.41%US$26,880Sep 30, 2026
Hrt Financial LP17,4930.35%US$22,000Sep 30, 2026
XTX Topco Ltd15,0400.30%US$19,251Sep 30, 2026
McKinley Carter Wealth Services, Inc.11,1930.22%US$14,328Sep 30, 2026
UBS6,1870.12%US$7,919Sep 30, 2026
Robinhood Markets, Inc.2,0400.04%US$2,632Sep 30, 2026
All 18 holders
HolderSharesOf the companyValueAs of
Morgan Stanley2,0000.04%US$2,560Sep 30, 2026
Tower Research Capital LLC (TRC)1,3470.03%US$1,724Sep 30, 2026
Osaic Holdings, Inc.500<0.01%US$625Sep 30, 2026
BlackRock113<0.01%US$145Sep 30, 2026
Harbour Investments, Inc.15<0.01%US$19Sep 30, 2026
Quaker Wealth Management, LLC3<0.01%US$4Sep 30, 2026
Fidelity1<0.01%US$1Sep 30, 2026
Danske Bank A/S1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund18,7870.37%US$23,108Jun 30, 2026
Fidelity Extended Market Index Fund13,9340.28%US$15,885May 31, 2026
Fidelity Total Market Index Fund2,5280.05%US$2,882May 31, 2026
Fidelity Series Total Market Index Fund2,3140.05%US$2,638May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Sharon Barbari
Other companies: VYNE Therapeutics Inc. (Director · Since at least Jul 19, 2021); Cytokinetics, Incorporated (EVP, Finance & CFO · Mar 1, 2006 – Feb 28, 2017 · Past)
Director · Mar 26, 2014 – Mar 1, 2018 · Past
Gregory M French
Other companies: Pulmatrix, Inc. (Director · Mar 21, 2014 – Apr 30, 2015 · Past)
Director · Jan 24, 2007 – Dec 18, 2013 · Past
Jerome J Dvonch
Other companies: NeoGenomics, Inc. (Prinicpal Accounting Officer · May 2, 2011 – May 2, 2011 · Past)
Chief Financial Officer · Since at least Sep 8, 2020
Amy Moss TromblyChief Executive Officer · Since at least Sep 27, 2019
Arturo AngelSenior Vice President of Regulatory, Quality and Product Development · Jan 28, 2026 – Nov 5, 2026 · Past
Bruce ThorntonExecutive VP and COO · Since at least Jan 7, 2021
Jay E BirnbaumDirector · Since at least Jan 14, 2022
John McLaughlinDirector · Since at least Mar 1, 2013
Philippe WeigerstorferDirector · Since at least Sep 19, 2018
Robert Allen NortheyExe. VP of Research and Dev. · Sep 1, 2015 – Jun 29, 2017 · Past
All 13 people
PersonSeat
Robert Grant EdwardsChief Financial Officer · Apr 14, 2020 – Apr 23, 2020 · Past
Russell Joseph HarrisonDirector · Feb 26, 2014 – May 30, 2018 · Past
Vanessa JacobyDirector · Since at least Jan 28, 2026

Open People

Log in to ask 6ix AI your own questions about Sonoma Pharmaceuticals, Inc.